Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials.
Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials.
复制标题
DOI：
10.3390/ijms17060928
复制
发表时间：
2016-06-13
影响因子：
5.6
通讯作者：
Gil A
中科院分区：
文献类型：
--
作者：
Sáez-Lara MJ;Robles-Sanchez C;Ruiz-Ojeda FJ;Plaza-Diaz J;Gil A
在过去十年中，益生菌和合生元在预防和治疗不同疾病中的使用急剧增加。益生菌和合生元都是功能性食品和营养保健品的众所周知的成分，并且可以提供有益的健康效果，因为它们可以影响肠道微生物生态和免疫力。本研究回顾了益生菌和合生元在人体随机临床试验中对肥胖、胰岛素抵抗综合征 (IRS)、2 型糖尿病 (T2D) 和非酒精性脂肪肝 (NAFLD) 的影响。选择益生菌和合生元对肥胖患者有有益作用，主要影响体重指数和脂肪量。一些益生菌对 IRS 具有有益作用，可降低细胞粘附分子 1 水平，合生元可降低胰岛素抵抗和血脂水平。此外，精选益生菌可改善 2 型糖尿病患者的碳水化合物代谢、空腹血糖、胰岛素敏感性和抗氧化状态，并减少代谢应激。一些益生菌和合生元改善了 NAFLD 患者的肝脏和代谢参数。本综述中显示的数据部分支持口服益生菌和合生元作为预防和治疗肥胖、IRS、T2D 和 NAFLD 的辅助佐剂。然而，需要进一步的研究来了解益生菌和合生元如何影响这些代谢紊乱的确切机制。
The use of probiotics and synbiotics in the prevention and treatment of different disorders has dramatically increased over the last decade. Both probiotics and synbiotics are well known ingredients of functional foods and nutraceuticals and may provide beneficial health effects because they can influence the intestinal microbial ecology and immunity. The present study reviews the effects of probiotics and synbiotics on obesity, insulin resistance syndrome (IRS), type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD) in human randomized clinical trials. Select probiotics and synbiotics provided beneficial effects in patients with obesity, mainly affecting the body mass index and fat mass. Some probiotics had beneficial effects on IRS, decreasing the cell adhesion molecule-1 levels, and the synbiotics decreased the insulin resistance and plasma lipid levels. Moreover, select probiotics improved the carbohydrate metabolism, fasting blood glucose, insulin sensitivity and antioxidant status and also reduced metabolic stress in subjects with T2D. Some probiotics and synbiotics improved the liver and metabolic parameters in patients with NAFLD. The oral intake of probiotics and synbiotics as co-adjuvants for the prevention and treatment of obesity, IRS, T2D and NAFLD is partially supported by the data shown in the present review. However, further studies are required to understand the precise mechanism of how probiotics and synbiotics affect these metabolic disorders.